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Comparison of Efficacy of Long-term Oral Treatment with
Telmisartan and Benazepril in Cats with Chronic Kidney Disease
U. Sent, R. G€ossl, J. Elliott, H. M. Syme, and T. Zimmering
Background: The efficacy and benefits of telmisartan in cats with chronic kidney disease (CKD) have not previously been
reported.
Hypothesis: Long-term treatment of cats with CKD using telmisartan decreases urine protein-to-creatinine ratio (UP/C)
similar to benazepril.
Animals: Two-hundred and twenty-four client-owned adult cats with CKD.
Methods: Prospective, multicenter, controlled, randomized, parallel group, blinded clinical trial with noninferiority design.
Cats were allocated in a 1 : 1 ratio to either telmisartan (1 mg/kg; n = 112) or benazepril (0.5–1.0 mg/kg; n = 112) PO q24 h.
The primary endpoint was prospectively defined as the change in proteinuria (benazepril:telmisartan) based on a log trans-
formed weighted average of UP/C change from baseline (AUC 0?t/t) as a percentage compared using a confidence interval
(CI) approach. Changes of UP/C from baseline were assessed on all study days and corrected for multiple comparisons.
Results: Telmisartan proved noninferior to benazepril in controlling proteinuria (CI, 0.035 to 0.268). At Day 180, UP/C
compared to baseline in the telmisartan group was significantly lower (0.05  0.31; P = .016), whereas in the benazepril
group the change (0.02  0.48) was not statistically significant (P = .136). Similar results were obtained at all assessment
points with significant decrease in UP/C occurring with telmisartan but not benazepril.
Conclusion and Clinical Importance: Both telmisartan and benazepril were well tolerated and safe. Telmisartan proved to
be noninferior to benazepril and significantly decreased proteinuria relative to baseline at all assessment points whereas bena-
zepril did not.
Key words: ACE inhibitor; Angiotensin II receptor blocker; Benazepril; Proteinuria.
Chronic kidney disease (CKD) is irreversible, pro-gressive, and one of the most common medical rea-
sons for medical evaluation of older cats. The prevalence
increases with age and up to 35% of the geriatric cat
population is affected.1,2 Clinical signs such as polyuria
and polydipsia, lethargy, decreased appetite and weight
loss often are described, and a considerable effect of
CKD on the quality of life can be assumed.3 Further-
more, CKD negatively impacts survival, with an average
life expectancy of 1–3 years once clinical signs become
apparent.4,5 Early management can improve quality of
life and prognosis.1,6 Compensatory chronic activation
of the renin–angiotensin–aldosterone system (RAAS) in
CKD to maintain glomerular filtration rate (GFR)
increases angiotensin-II (AT-II) production with renal
concentrations exceeding plasma concentrations.7,8
Angiotensin-II is a central mediator of renal injury
because of its ability to produce glomerular hypertension
that results in glomerular damage, proteinuria, and acti-
vation of pro-inflammatory and profibrotic pathways.9,10
Furthermore, even mild proteinuria is strongly associ-
ated with and predictive of onset of azotemia,11 progres-
sion of CKD,12 and survival in both humans and
cats.4,13 Several AT-II receptors have been identified.14
The major detrimental renal effects of AT-II described
above are mediated by AT1 receptors. The AT2 receptors
modulate actions of AT-II that are renoprotective,
namely vasodilation, natriuresis, inhibition of renin
secretion, and anti-inflammatory, anti-ischemic and
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antifibrotic effects. The expression of the AT2 receptor is
increased in pathologic circumstances.15,16
Angiotensin converting enzyme (ACE)-inhibitors pre-
vent enzymatic conversion of angiotensin-I, decreasing
AT-II concentrations. However, in mammals, including
the cat, alternative pathways (ACE-escape) exist for
AT-II generation.17–19 Although increased plasma renin
activity has been reported during treatment with angio-
tensin receptor blockers (ARBs) in humans, a phe-
nomenon that also could partially overcome
competitive receptor blockade, this phenomenon seems
to be without clinical relevance.20
The ARBs, such as telmisartan,a selectively block the
AT1 receptor with high affinity and displace AT-II,
while leaving beneficial effects of the AT2 receptor acti-
vation unaffected. Furthermore, the efficacy of ARBs is
unaffected by ACE-escape mechanisms. The renoprotec-
tive properties of telmisartan have been demonstrated
in ex vivo models and in vivo studies in human patients
with diabetic and nondiabetic nephropathies.21–24 In
contrast to other ARBs, telmisartan also is a partial
agonist of the peroxisome proliferator-activated recep-
tor gamma (PPAR-c) receptor and its renoprotective
properties are increased by this dual action.22,23,25
There are no published studies on telmisartan or
other ARBs in cats with naturally occurring CKD,
whereas benazepril has been shown to decrease the
time-averaged urine protein-to-creatinine ratio (UP/C)
relative to that of placebo-treated cats.28 The primary
objective of this study was to compare the antiprotein-
uric effect of telmisartan with that of benazepril in cats
with naturally occurring CKD. Additional variables
were evaluated to assess effect on quality of life.
Materials and Methods
Animals
Client-owned adult cats suspected of having CKD were
screened for CKD at 48 centers across Europe including: Germany
(15), France (12), United Kingdom (11), Netherlands (4) Belgium
(4), and Italy (2).
Inclusion Criteria
Cats of either sex were eligible for inclusion only if owner
informed consent was given and they were >2.0 kg body weight and
diagnosed with clinically stable CKD International Renal Interest
Society (IRIS)27 stage 2–3. Diagnosis of CKD was based on history,
physical examination and laboratory findings. The following criteria
had to be met: plasma or serum creatinine concentration ≥1.6 and
<5.0 mg/dL, urine specific gravity <1.035, UP/C ≥ 0.2 and <2.0,
plasma or serum T4 concentrations ≤3.1 lg/dL, and systolic blood
pressure (SBP) ≤170 mmHg. Cats with SBP > 170–<180 mmHg were
eligible if they had been stable on amlodipine treatment for ≥4 weeks.
Cats receiving a renal diet were eligible if they had received the
diet for ≥4 weeks.
Exclusion Criteria
Cats were ineligible for inclusion if they had received ACEin-
hibitors, ARBs or other vasodilating agents, or diuretics (eg, furo-
semide) <14 days before screening or had their diet changed
<4 weeks before screening. Cats with urinary tract infection identi-
fied by urine cytology and culture (>1,000 colony forming units
[CFU]/mL), palpably enlarged kidneys, renal neoplasia, pre- or
postrenal azotemia, heart failure (New York Hear Association
[NYHA] class II, III, IV), acute kidney injury, pregnancy, or lacta-
tion were excluded.
Study Design
A multicenter prospective, randomized, investigator-blinded,
positive-controlled, parallel group design was adopted. At each
study site, the investigator was blinded by use of a dispenser, who
was responsible for allocation and dispensing of medication as well
as its return only. The outer package of both medications was
visually identical, and the weight of each package was adjusted to
prevent differentiation between medications to ensure that all per-
sons involved in the evaluation were not aware of the medication
given.
Client-owned cats were allocated to receive telmisartana or
benazeprilb (1 : 1 ratio). The protocol was prepared in consulta-
tion with independent experts in CKD of cats and approved by
European regulatory agencies and by an ethical review committee
at all sites where required. The study was powered to assess nonin-
feriority regarding the primary endpoint UP/C change from base-
line of telmisartan against benazepril, and was conducted
according to good clinical practice (GCP)c guidelines (VICH
GL9).
The randomization sequence was generated as a single list,
which was held by a single center, not located at a study site.
Procedures were available to allow unblinding in the event of
medical emergency.
An solution of telmisartana was administered PO by the cat
owner at a dosage of 1 mg/kg (0.25 mL/kg) q24 h. Benazeprilb
was administered at 0.5–1.0 mg/kg PO q24 h as a flavored 2.5 mg
tablet in accordance with the product label. Cats >2 and <5 kg in
weight received 1 tablet, and cats >5 and <10 kg body weight
received 2 tablets.
Routine treatments with no impact on CKD (eg, vaccinations,
antiparasitic drugs) were allowed. Any concomitant treatment was
documented. Amlodipine (0.625–1.25 mg PO q24 h) was allowed
if cats had been stabilized for ≥4 weeks before inclusion, and treat-
ment was continuous. Antimicrobial treatment was not permitted
in the 7 or 21 days before inclusion for short-acting and long-act-
ing agents, respectively. If sedation of a cat was required for a
diagnostic procedure during the study, a standard sedation proto-
col was used. Anti-inflammatory or anti-infective treatment was
only permitted as acute treatment.
Schedule of Events
Cats with a history typical of CKD or those >7 years and sus-
pected of having CKD at a routine screening underwent further
examination to diagnose and stage CKD based on IRIS guide-
lines.27 Fasted serum creatinine concentrations were determined in
well-hydrated cats at least twice (screening and Day 0). Cystocen-
tesis was performed for urine collection whenever possible. Urinal-
ysis was performed on site. Laboratory examinations were
conducted at IDEXX Laboratory Germany, except for those from
the United Kingdom, which were performed at the IDEXX Labo-
ratory United Kingdom. A cross-validation of the 2 IDEXX Lab-
oratories confirmed their comparability.
Systolic blood pressure was measured, if indicated, by an indi-
rect method for safety purposes only, using a consistent method
for an individual cat (usually Doppler ultrasound examination).
The inclusion date (Day 0) was the day on which the cat first
received telmisartan or benazepril. Detailed follow-up physical
2 Sent et al
examinations and urinalyses were scheduled on Days 7, 30, 60, 90,
120, and 180. Routine hematology and blood biochemistry were
repeated on Days 30, 90, and 180. Additional diagnostic tests
could be undertaken whenever considered indicated by the investi-
gator. All adverse events (AEs) were reported in accordance with
local regulations.
Outcome Measures
The primary efficacy outcome of the study was prospectively
defined as the decrease in proteinuria, measured by UP/C, com-
pared to baseline. Telmisartan was hypothesized to be similarly
efficacious to benazepril. Representing secondary efficacy variables,
the changes in general demeanor and appetite in comparison to
baseline were recorded as surrogates for quality of life variables.
These variables were assessed by the owners who scored appetite
as normal, increased, decreased, or no eating and demeanor as
normal, alert, listless, or lethargic.
The number of treatment failures, defined as death or eutha-
nasia of any cause, owner noncompliance or deterioration of
clinical signs requiring hospitalization, was recorded. Further-
more, according to GCP any AE, defined as “any observation in
animals that is unfavorable and unintended and occurs after the
use of a veterinary product or a investigational veterinary pro-
duct, whether or not considered to be product related”, was
recorded.
Statistical Methods
Cats included in the efficacy analysis were required to be fol-
lowed to Day 90 (per-protocol-population dataset [PPS], Fig 1)
whereas all treated cats (intention-to-treat [ITT] population) were
included in the safety analysis. Baseline characteristics of the
groups were compared for homogeneity.
The same approach was followed as used in the reference
study,28 in which benazepril was shown to be superior to placebo
in a randomized controlled trial assessing the effect of treatment
on time-averaged proteinuria (area under the curve [AUC] UP/C).
Because internal pilot and published data4 showed a skewed distri-
bution of the calculated AUC UP/C values, sample size determina-
tion and statistical analysis of the primary efficacy variable were
based on the log transformed AUC UP/C values. For the primary
efficacy analysis, a summary value based on a log transformed
weighted average of UP/C change from baseline (AUC UP/C 0?
t/t) in percentage of each cat over time was calculated (Day
0 = 100%). The AUC principle was used to account for progres-
sive loss of cats to follow-up as used in the reference study.28 Non-
inferiority to benazepril was based on a confidence interval (CI)
approach using the normal approximation.29 The null hypothesis
“inferiority of treatment to positive control” was rejected if the
95% 2-sided CI of the log (AUC UP/C 0?t/t) difference lay
entirely above the noninferiority margin D(0.108 to 0.116). A
noninferiority margin of D = 0.108 on the log scale, corresponding
Fig 1. Participant flow. *More than 1 reason for exclusion possible. **Benazepril group: anemia; telmisartan group: increase in renal
parameters (2 cats), uremic crisis, anorexia, cerebellar mass on MRI, intra-abdominal neoplasia, hind limb ataxia (1 cat for each). ***Ex-
clusion UPC “>2 of 5” Rule: For the first 5-study days at most 2 missing or excluded because of bacteria contamination (CFU >1,000/mL)
UPC values are considered to be acceptable to yield reliable AUC values.
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to a ratio AUC(IVP)/AUC(CP) of approximately 1.11, was assumed
and determined from an internal pilot study with 37 animals over
8–12 weeks in which an average AUC 0?t/t value of 106.83%
with a SD of 28.28% was observed. Based on these data, an abso-
lute margin of 119% corresponding to a relative margin of
approximately 1.11 was defined a priori and was accepted as clini-
cally meaningful by the licensing authorities.
In addition, absolute change in UP/C from baseline was analyzed
within each group using a 1-sample signed-rank test. P-values were
adjusted for multiplicity by the Bonferroni–Holm procedure.26
Other secondary efficacy variables, including behavioral changes
and number of treatment failures, were summarized statistically
for the PPS population. Secondary efficacy variables were not
compared between groups statistically.
In accordance with the recommendations of CONSORT,30 a
valid assessment of this noninferiority study is provided. Statistical
analyses were performed using the SAS System Version 9.2.d
P < .05 was considered to indicate significance.
Results
Cats were recruited between March 2008 and August
2010, with case follow-up completed in January 2011.
More than 2000 cats were screened and 224 cats (ITT
Table 1. Baseline characteristics at inclusion (intention-to-treat population).
Variable
Benazepril (n = 112) Telmisartan (n = 112)
Mean (min–max) No (%) Mean (min–max) No (%)
Age (years) 12.8 (2–22) 13.6 (3–21)
Weight (kg) 4.3 (2–11) 4.4 (2–9)
Gender
Female 58 (51,8) 55 (49.1)
Male 54 (48,2) 57 (50.9)
Neutered 104 (92,9) 106 (94.6)
Breed
DLH 6 (5.4) 9 (8.0)
DSH 72 (64.3) 75 (67.0)
Mixed 9 (8.0) 4 (3.6)
Other 20 (17.9) 16 (14.3)
Persian 5 (4.5) 8 (7.1)
Serum Biochemistry % >ULN % >ULN
TT4 (lg/dL) 1.9 (0.3–5.4) 0.9 1.8 (0.3–4.3) 0.0
Creatinine (mg/dL)a 2.4 (1.6–6.6) 58 2.5 (1.1–6.6) 64.3
Urea (BUN) (mg/dL) 48.7 (21.3–139.8) 84.8 52.1 (23.3–299.4) 79.5
Sodium (mEq/L) 154.9 (147.0–167.0) 0.9 155.3 (147.6–174.0) 1.8
Potassium (mEql/L) 4.5 (3.0–6.4) 7.1 4.5 (3.0–8.1b) 3.6
Calcium (mg/dL) 10.4 (7.6–13.2) 6.3 10.4 (8.0–13.2) 2.7
Phosphate (mg/dL) 5.0 (2.2–10.2) 7.1 5.0 (2.2–15.8) 6.3
Albumin (mg/dL) 3.4 (2.2–4.6) 0.0 3.4 (2.6–4.5) 0.0
ALT (U/L) 65.2 (22.0–210.8) 1.8 65.1 (21.4–279.4) 1.8
ALP (U/L) 32.8 (10.0–111.8) 0.9 30.4 (12.0–129.0) 0.9
CBC % <LLN, >ULN %<LLN, >ULN
RBCc 10 9 12/L 7.5 (3.4–10.9) <3.6, >6.3 8.0 (3.9–14.6) <2.7, >10.7
HGB g/L 108.2 (55–170) <17.3, >1.2 113.4 (67–170) <11.5, >2.6
HCT % 34.9 (19.0–54.0) <10.8, >1.8 37.3 (21.0–69.8) <5.4, >3.6
WBCc g/L 10.7 (1.9–28.9) <17.1, >18.9 9.6 (2.8–49.2) <17.0, >8.0
Urine Variables
Specific gravityc 1.022 1.022
UPC 0.41 (0.1–2.2) 0.41 (0.1–3.0)
Systolic BP (mmHg) 147.7 (95–180) 146.2 (98–176)
Amlodipine treatmentc 6 (5.4) 10 (8.9)
Kidney diet 36 (32.1) 39 (34.8)
Disease History Mean Duration (years) Mean Duration (years)
PU/PD 0.66 63 (56.3) 0.56 71 (63.4)
Decreased appetite 0.41 28 (25.0) 0.36 33 (29.5)
Weight loss 0.53 48c (42.9) 0.52 56 (50.0)
Palpably small kidneys 21 (18.8) 18 (16.1)
aUpper reference limit (ULN) laboratory 2.0 mg/dL.
bLaboratory error suspected at D0, at recheck examinations potassium levels of this patient were well within reference ranges.
cOne missing value, LLN/ULN = lower/upper reference limit.
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population) were recruited with 112 cats randomized to
each group (Fig 1). Clinical signs suggestive of CKD
were present for >3 months in most cats before inclu-
sion. The baseline demographics, and clinical and labo-
ratory characteristics were distributed homogeneously
between groups (Table 1). Cats >11 years predominated
in both groups, which had similar mean and median
ages (Table 1). Most cats (approximately 80%) were
classified as IRIS CKD stage 2 (84/112 and 91/112 for
telmisartan and benazepril, respectively). Four cats in
IRIS CKD stage 4 were included in the study as a pro-
tocol deviation (Table 2), the remainder being IRIS
CKD stage 3. Most cats enrolled were borderline pro-
teinuric (UP/C 0.2–0.4), with similar numbers in each
treatment group; 3 cats with UP/C < 0.2 were included
as a protocol deviation because all other criteria for
CKD were fulfilled (Table 2). Fifty-one percent of the
cats had SBP results in the mild to moderate hyperten-
sion class (IRIS classification; 150–179 mmHg;
Table 2). A small number of cats with SBP >170 but
<180 mmHg that were stabilized on amlodipine treat-
ment before Day 0 was included in both groups
(Table 1). Approximately, 30% of cats in both groups
were being fed a renal diet at inclusion (Table 1). Devi-
ations from planned time schedule were unavoidable
under field conditions. They did not exceed 12 days and
were considered to be of no influence on the general
study outcome.
The primary variable log (AUC UP/C 0?t/t) based
on the CI approach showed noninferiority of telmisar-
tan compared to benazepril in the PPS population
(n = 176) and in the ITT population (n = 224).
Although the study was designed as a noninferiority
study, telmisartan was close to being superior to bena-
zepril (Fig 2).
The changes from baseline over time are presented in
Table 3. On Day 180, overall mean UP/C values were
numerically lower in both groups compared to baseline.
In the telmisartan group, the mean decrease
(0.05  0.31) was significantly different from baseline
(P = .016). In the benazepril group, the mean decrease
(0.02  0.48) was not significantly different from
baseline (P = .136). Furthermore, in the telmisartan
group statistically significant decreases in UP/C were
found at all assessment points, whereas in the benaze-
pril group no statistical change in UP/C compared to
baseline was found at any assessment point. These find-
ings also are reflected in the number of cats that chan-
ged from being classified as proteinuric at baseline to
borderline proteinuric or nonproteinuric at Day 180,
which was 30.8% (4/13) in the benazepril and 57.2%
(8/14) in the telmisartan group. In cats that were classi-
fied as borderline proteinuric at baseline the number of
cats that either shifted to nonproteinuric (approximately
33%) or remained borderline proteinuric (approxi-
mately 50%) at Day 180 was comparable in both
groups with 85.7% (54/63) in benazepril and 87.9%
(51/58) in telmisartan-treated cats.
The majority of cats completed the study, and the
proportion of cats removed from the study was compa-
rable in both treatment groups (Fig 1). The percentage
of treatment failures in the PPS population was 15.3%
(13/85) for telmisartan and 19.8% (18/91) for benaze-
pril-treated cats. The number of deaths in telmisartan-
treated cats (ITT population) was 13/112 and 22/112
for benazepril-treated cats. The changes in general
behavior indicative of quality of life in treated cats were
assessed relative to baseline to describe clinical benefit.
Cat owners reported the most visible change in behavior
during the first 60 days with a small numerical increase
in active cats being reported in both groups. Most cats
(approximately 80%) had normal appetite and little
change in appetite was seen throughout the study.
Telmisartan and benazepril were well tolerated and
most of the AEs reported were typical of the signs of
Table 2. Telmisartan and Benazepril Group (inten-
tion-to-treat population, n = 112 each), IRIS stage at
baseline including substaging.
Telmisartan
(n = 112)a
IRIS
Stage 2a
(n = 36)
IRIS
Stage 2b
(n = 48)
IRIS Stage
3 (n = 21)
IRIS Stage
4 (n = 3)b
Substaging by SBP
<150 mmHg 17 30 6 1
150–159 mmHg 11 5 5 1
160–179 mmHg 8 13 10 0
≥180 mmHg 0 0 0 0
Substaging by UP/Ca
<0.2 1 1 0 0
0.2–0.4 26 40 13 0
>0.4 9 8 2
Benazepril
(n = 112)
IRIS
Stage 2a
(n = 47)
IRIS
Stage 2b
(n = 44)
IRIS Stage
3 (n = 19)
IRIS Stage
4 (n = 2)
Substaging by SBP
<150 mmHg 24 18 8 1
150–159 mmHg 7 9 5 1
160–179 mmHg 16 16 6 0
≥180 mmHg 0 1 0 0
Substaging by UP/C
<0.2 0 1 0 0
0.2–0.4 42 31 15 1
>0.4 5 12 4 1
aIRIS stage 1 (n = 4) not shown.
bOne missing value for IRIS 4.
Fig 2. Results of the noninferiority and superiority analysis for
the primary variable log AUC 0?t/t in the PPS-population. The
delta (Δ) indicates the noninferiority margin. The observed 95%
confidence interval limits (CL) for the treatment difference are
shown as the shaded area.
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CKD, and the majority was unlikely to be related to
treatment. Adverse events that were reported in both
groups (benazepril: 65 cats and telmisartan: 61 cats with
≥1 AE) included signs of deterioration of CKD, gas-
trointestinal disorders, and very few cats with urinary
tract infections, cardiac, oral cavity, skin, or respiratory
disorders, neurological signs, or neoplasia. Figure 1
gives details of the AEs that resulted in withdrawal of
cases from the study before Day 90.
At the end of the study, the mean values for red
blood cell count (RBC), hemoglobin (HGB) and hemat-
ocrit (HCT) were comparable between treatment
groups. Clinical evidence of anemia was reported in 2
cats (1 in each group) with CKD; both also were receiv-
ing amlodipine. No clinically relevant changes in serum
calcium, potassium, sodium, or phosphate concentra-
tions were recorded in either treatment group.
Discussion
The aim of our study was to compare the efficacy of
telmisartan against benazepril with respect to the pri-
mary endpoint, change in UP/C from baseline.
Although the study was designed as a noninferiority
study, telmisartan was close to meeting the a priori
agreed upon criterion for superiority to benazepril.
The UP/C was significantly decreased compared to
baseline at all assessment points in telmisartan-treated
cats, whereas statistical significance was not reached for
benazepril-treated cats.
Telmisartana, a selective AT1 receptor antagonist,
does not bind to AT2 receptors or other key physiologi-
cally important receptors or enzymes at therapeutic
concentrations.31 Selective blockade of AT1 receptors
offers an alternative approach to the modulation of the
RAAS. Telmisartan is licensed for 2 indications in
human adults: the treatment of essential hypertension,
as well as the reduction in cardiovascular morbidity
(cardiovascular prevention) in patients with
atherothrombotic cardiovascular disease or type 2 dia-
betes mellitus with target organ damage. Renoprotective
properties of telmisartan in humans are thought to be
related to selective blockade of AT1 and partial ago-
nism of PPAR-c receptors.23,32 The apparently more
pronounced decrease in proteinuria in cats in this study
might be explained by this dual mode of action of
telmisartan or circumvention of potential ACE-escape
mechanisms.
A large number of cats had to be screened to identify
suitable cats with CKD for inclusion in this study. The
study population (predominantly IRIS CKD stage 2)
was considered to be appropriate for the intended target
population because early treatment is logical if the ther-
apeutic rationale is that of slowing progression. Cats in
this study were older and had a slightly higher body
weight compared to the reference study,28 findings that
probably are indicative of recent demographic changes
in the cat population.
According to the requirements of CONSORT,30 effi-
cacy of the reference treatment had been established in
a randomized placebo-controlled study.28 For a valid
assessment of noninferiority, it is necessary that partici-
pants, study conduct, and outcome measures are similar
to the reference study.28 This study closely matched the
reference study with respect to study design, target pop-
ulation, and outcome measures. The primary outcome,
decrease in proteinuria, calculated by UP/C change
from baseline (as assessed by the AUC UP/C 0?t/t),
was chosen because it was used in the reference study.
Furthermore, proteinuria has been previously demon-
strated to be an independent predictor of progression
and survival of cats with CKD.4,11–13
Limitations reported for the reference study28 were
addressed to allow an unbiased assessment of outcome in
this study. Thus, before inclusion, urine culture and
screening for hyperthyroidism were undertaken. Hyper-
thyroidism is a known comorbidity in cats with CKD and
may influence proteinuria and liver enzyme activity.33 In
order not to bias efficacy and safety conclusions, cats with
a T4 concentration >3.1 lg/dL, which is within the upper
third of the reference range, were excluded, with the aim
of excluding cats with concomitant hyperthyroidism and
Table 3. UP/C changes from baseline by treatment and study day for the PPS population.
Treatment Day N Mean SD Median Range IQ Range P-value
Benazepril 7 87 0.06 0.25 0.0 1.4 to 1.0 0.10 .040
30 88 0.06 0.28 0.0 1.5 to 0.5 0.15 .023
60 87 0.07 0.38 0.0 1.6 to 1.1 0.10 .046
90 86 +0.06 0.61 0.0 1.5 to 3.5 0.20 .072
120 85 +0.06 0.77 0.1 1.6 to 5.2 0.20 .143
180 76 0.02 0.48 0.0 1.5 to 2.3 0.20 .136
Telmisartan 7 80 0.07 0.28 0.1 1.7 to 1.0 0.10 <.0001a
30 83 0.08 0.26 0.1 1.6 to 0.5 0.10 <.0001a
60 82 0.09 0.33 0.1 1.7 to 0.8 0.10 .0002a
90 83 0.08 0.31 0.1 1.4 to 1.3 0.20 <.0001a
120 75 0.02 0.51 0.1 1.6 to 2.4 0.20 .002a
180 72 0.05 0.31 0.0 1.1 to 1.1 0.10 .016a
The P-values are adjusted for multiplicity by the Bonferroni–Holm procedure (P-values sorted from lowest to highest and compared to
the adjusted P-values (ie, .0083; .01; .0125; .016; .025; .05).
aSignificantly different from baseline.
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CKD in which suppressed T4 concentrations may compli-
cate diagnosis of hyperthyroidism.34
More than 90% of urine samples collected in this
study was obtained by cystocentesis, which compares
favorably with 60% collected by this method in the ref-
erence study.28 Abnormal urine sediment triggered urine
culture in this study. In 14 cats (5 in the benazepril and
9 in the telmisartan group), bacterial urinary tract infec-
tion was confirmed leading to exclusion from the effi-
cacy analysis.
Benazepril previously has been reported to decrease
proteinuria in cats with CKD in comparison to pla-
cebo when assessed over a variable follow-up period,
but not to significantly improve survival time,28 or
slow CKD progression.35 The reference study showed
that time-averaged UP/C increased above baseline in
the placebo group, and benazepril seemed to prevent
this increase. Similar to the reference study,28 in this
study, benazepril prevented an increase in proteinuria
while a decrease in proteinuria relative to baseline after
180 days was present only in telmisartan-treated cats.
This study was conducted for 180 days, thus the effect
of telmisartan on survival of cats with CKD could not
be evaluated. Additional studies are warranted to
assess telmisartan’s effect on survival time in cats with
CKD.
It might be questioned whether the decrease in UP/C
relative to baseline seen in this study is clinically rele-
vant. A previous study demonstrated that high UP/C
(median value of 0.26 versus 0.15 in progressive versus
nonprogressive cases, respectively) and high plasma
phosphate concentration at diagnosis are significant
independent risk factors for progression of azotemia in
cats with CKD and that small differences in UP/C at
diagnosis are clinically relevant.12 In a postmortem
study, proteinuria was associated with interstitial fibro-
sis and glomerular hypertrophy.36 These associations
between proteinuria and negative CKD outcomes do
not prove causality but provide the rationale for investi-
gating telmisartan’s effect on progression of CKD or
survival time in cats because this study demonstrated
telmisartan’s efficacy in decreasing proteinuria. These
associations also support the contention that, if a
decrease in proteinuria is renoprotective and prolongs
survival in the cats with CKD (which remains to be
proven), relatively small decreases in UP/C (eg, from
proteinuric to borderline proteinuric or from borderline
proteinuric to nonproteinuric) or prevention of an
increases in UP/C over time could be clinically relevant.
Unlike the reference study,28 in our study SBP was
monitored at inclusion and at study conclusion, because
hypertension is known to be associated with CKD and
proteinuria4 in cats. The SBP of the PPS population at
the end of the study was comparable to baseline in both
groups. Our study was not designed to assess antihyper-
tensive efficacy, and additional work is necessary to
assess effects on blood pressure. In the ITT population,
16 cats (Table 1), and in the PPS population 11 cats
were pretreated with amlodipine (3 and 8, in the bena-
zepril and telmisartan group, respectively). To exclude a
potential effect of amlodipine on the primary efficacy
variable in the both groups, the same analysis was per-
formed without the amlodipine-treated cats, with almost
the same results: observed treatment difference for the
primary variable log AUC?t/t: 0.112, and significant
change in overall mean UP/C value (P = .013) for the
telmisartan but not (P = .16) for the benazepril group.
Furthermore, the percentages of cats classified as pro-
teinuric, borderline proteinuric or nonproteinuric at
Day 180 in comparison to baseline were very similar
when amlodipine-treated cats were excluded.
Hematology variables were monitored to assess
changes in RBC counts, which might be caused either
by progression of CKD or by drug interaction with the
RAAS. At baseline, approximately 3% of cats had
RBC counts below the reference range (5.0 9 1012/L).
In the reference study,28 approximately 10% of the cats
had RBC counts below the reference range at baseline.
The mean RBC counts were comparable between
groups and within the reference range at the end of the
study. The proportion of cats with RBC counts below
the reference range slightly increased in both groups by
study end. Clinical evidence of anemia was reported in
2 cats (1 per group). Both cats received concomitant
amlodipine treatment, and thus the role of treatment
could not be assessed. Medications that inhibit the
RAAS may decrease red cell mass by blocking the
effects of AT-II on erythropoiesis.37,38 The results of
this study suggest this potential decrease in RBC count
is not clinically relevant. Hypokalemia occurs in 20–
25% of cats with CKD.39,40 In this study, neither hypo-
nor hyperkalemia was found in any cat over the study
period.
Because a primary requirement for the administration
of any medication is safety, our study also collected
data on AEs. The number of deaths and withdrawals
from the study was small in both groups. Adverse
events reported in both groups were those expected for
cats with CKD and in most cases were judged as unli-
kely to be treatment related.
In conclusion, telmisartan effectively decreased pro-
teinuria and was safe for treatment of cats with CKD.
For the primary variable, telmisartan was at least as
effective as benazepril. Indeed, telmisartan’s antiprotein-
uric effect appeared to be more pronounced because sig-
nificant decreases in UP/C compared to baseline were
identified for telmisartan but not benazepril. The results
of our study indicated that telmisartan was a safe and
effective treatment to decrease proteinuria associated
with CKD in cats.
Footnotes
a Semintra oral solution for cats (telmisartan 4 mg/mL), Boehrin-
ger Ingelheim Vetmedica GmbH, Ingelheim, Germany
b Fortekor 2.5, flavored benazepril, Novartis Sante Animale S.A.S
Huningue Cedex, France
c VICH GL9 (GCP), London, UK, July 1, 2001
d SAS Institute Inc, Cary, NC
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